Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) COO Sells $271,782.30 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 2,631 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $271,782.30. Following the completion of the transaction, the chief operating officer directly owned 20,655 shares of the company’s stock, valued at $2,133,661.50. This represents a 11.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Peter Radovich also recently made the following trade(s):

• On Monday, January 26th, Peter Radovich sold 3,143 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $96.19, for a total transaction of $302,325.17.
• On Thursday, January 22nd, Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total transaction of $222,312.06.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $98.23 on Friday. The company has a market capitalization of $5.05 billion, a P/E ratio of -114.22 and a beta of 0.49. The company has a fifty day moving average price of $82.72 and a 200-day moving average price of $73.71. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. Mirum Pharmaceuticals, Inc. has a 52-week low of $36.88 and a 52-week high of $105.74.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The business had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. Mirum Pharmaceuticals had a negative return on equity of 16.47% and a negative net margin of 8.78%.Mirum Pharmaceuticals’s quarterly revenue was up 47.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.30) earnings per share. As a group, equities analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Dana Investment Advisors Inc. acquired a new position in Mirum Pharmaceuticals during the 4th quarter valued at about $482,000. Thrivent Financial for Lutherans bought a new stake in Mirum Pharmaceuticals in the 4th quarter worth about $3,306,000. VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in Mirum Pharmaceuticals by 101.6% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 6,450 shares of the company’s stock valued at $509,000 after buying an additional 3,250 shares during the last quarter. Swiss Life Asset Management Ltd bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $320,000. Finally, Nan Fung Trinity HK Ltd. boosted its stake in shares of Mirum Pharmaceuticals by 45.6% in the 4th quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock worth $17,969,000 after buying an additional 71,214 shares during the last quarter.

Analysts Set New Price Targets

MIRM has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $130.00 price objective on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. JMP Securities set a $95.00 price target on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 5th. Leerink Partners set a $100.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, December 10th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Finally, Stifel Nicolaus boosted their target price on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $107.25.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.